Flow cytometric quantitation of DNA and c-myc oncoprotein in archival biopsies of uterine cervix neoplasia

P. Hendy-Ilbs1, H. Cox1, G.I. Evan2 & J.V. Watson1

1 MRC Clinical Oncology Unit and 2 Ludwig Institute for Cancer Research, The Medical School, Hills Road, Cambridge CB2 2QH, UK.

Summary The c-myc nuclear associated oncoprotein has been quantitated simultaneously with DNA in nuclei extracted from archival biopsies of uterine cervix neoplasia. The oncoprotein and DNA were measured fluorometrically in a flow cyrometer using a mouse monoclonal antibody (MYC1-6E10) and propidium iodide. Normal biopsies exhibited higher oncoprotein levels than carcinomas (P<0.00001). Furthermore, the maximum fluorescence signal in the normal tissue occurred at a lower antibody concentration compared with tumour tissue. There was no correlation between oncoprotein levels and histological grade, stage of disease, age of the patients or prognosis in the carcinomas. Aneuploidy, defined as a distinct second peak separate from the diploid distribution, was not a significant feature. The c-myc oncoprotein nuclear content does not appear to be a prognostic indicator in carcinoma of the cervix from the results of these studies but there is clearly diagnostic potential, particularly for automated analysis of cervical screening.

Oncogenes are associated with proliferation control. The c-sis gene encodes a subunit of platelet derived growth factor (Doolittle et al., 1983; Waterfield et al., 1983). v-erb B and c-fms respectively encode the intracellular Br. sis does not appear to be a prostaglandin in cervical biopsies of the c-myc associated marker oncogene, p62c-myc (Evan & Hancock, 1985) have been developed (Evans et al., 1985). One of these antibodies has been used for histological localization of p62c-myc in both testicular cancer (Sikora et al., 1985) and in colonic neoplasia (Stewart et al., 1986) using immunocytochemical techniques. Quantitative methods have now been developed to assay nuclear associated p62c-myc in individual nuclei extracted from archival biopsies using flow cytometry (Watson et al., 1985). These methods have been used to analyse data in testicular cancer (Watson et al., 1986) and colonic neoplasia (Watson et al., submitted). In this paper we examine the p62c-myc nuclear content in normal and neoplastic cervical biopsies.

Patients and methods

Patients

A total of 127 patients attending the Weston Park Hospital Radiotherapy Department, Sheffield between 1971 and 1978 were included in the study. The only criteria of entry were that sufficient wax embedded punch biopsy material was available for the assay and that there were complete follow-up data. Sixty-four biopsies were from invasive carcinoma and 29 were from normal cervix. The remaining patients had cervical intraepithelial neoplasia (CIN) disease where 11, 9 and 14 were grades I, II and III respectively.

Anti-p62c-myc antibody

Full details of the methods for production of the anti-p62c-myc antibody are published elsewhere (Evans et al., 1985). Briefly, synthetic peptides were constructed to hydrophilic domains of the amino acid structure of the protein predicted from the DNA base sequence of the cloned gene (Niman et al., 1983). The peptides were used as the immunogens to produce mouse monoclonal antibodies which were purified from ascites and adjusted to a concentration of 2mgml⁻¹.

Histological examination

Most of the biopsies from patients with carcinoma (53/64) were examined histologically with 5μm sections cut adjacent to the thick sections used for flow cytometry. These contained a majority of malignant tissue which varied between ~60% and ~90%. All sections contained some normal cells. A minority of sections (10/53) contained a distinct inflammatory cell infiltrate in necrotic areas but this never exceeded ~20% of the total cells. Sections from 18/29 normal biopsies were similarly examined. The area of mucosa in the sections was assessed as being between ~40% (minimum) to ~80% (maximum) with the remainder being submucosal stroma. In all cases the sections contained exclusively squamous epithelium.

Imuno-peroxidase staining

A number of 4μm sections from both normal and malignant biopsies were stained for p62c-myc using MYC1-6E10 in a biotin-avidin system (Vectorstain, ABC Kit, Vector Labs) as previously described (Stewart et al., 1986).

Flow cytometry

Extraction of nuclei and staining The wax embedded punch biopsies were cut into 25μm sections, dewaxed then rehydrated. The tissue was then partially digested at 37°C in pepsin (Sigma Ltd) at a concentration of 5mg 100ml⁻¹ HCl pH 1.9 for 45min (Watson et al., 1985). This is a modified version of the method of Hedley et al. (1983) which releases nuclei by cytoplasmic digestion. The suspension containing nuclei was centrifuged at 200g, the supernatant was removed and the pellet was resuspended in 6ml PBS (pH 7.4) then aliquots of 1.0ml were placed in 6 Eppendorf tubes. After a further centrifugation the supernatants were removed and 4 pellets were resuspended in 10μl of anti-p62c-myc antibody (MYC1-6E10) at dilutions of 1:10, 1:31.6:1:100 and 1:316. Following incubation at room temperature for 45min the samples were centrifuged and the supernatants removed. The 4 samples plus one of the controls were then incubated for 60min with 20μl fluorescein isothiocyanate conjugated rabbit anti-mouse immunoglobulin (Dako Ltd., Denmark). The samples were then centrifuged, the supernatants were

Correspondence: J.V. Watson
Received 6 May 1986; and in revised form 9 October 1986.
removed and all samples were resuspended in 0.5 ml of a solution containing the DNA fluorochrome propidium iodide, PI, (Calbiochem, Ltd.) and ribonuclease both at a concentration of 0.05 mg ml⁻¹. Thus, one control contained only PI, the second control contained nuclei stained with PI and fluorescinated antibody (fluorescence control) and the remaining 4 samples were stained with PI plus the various MYC 1-6E10 concentrations and fluorescinated antibody.

Data collection and analysis The nuclei were analysed blind for DNA and p62-antiv simultaneously in the Cambridge MRC custom built dual laser flow cytometer (Watson, 1980, 1981) which incorporates a modified flow chamber to increase light collection efficiency (Watson et al., 1985). The Innova 70-5 argon ion laser (Coherent, Palo Alto, CA) was tuned to the 488 nm line at a light power of 100 mW which excites red fluorescence from the PI/DNA complex and green fluorescence from the fluorescein tagged oncoprotein. The green and red signals were separated by a 580 nm dichroic mirror (Zeiss Ltd) and the respective photodetectors were additionally guarded by a 515-560 nm band pass filter (green) and a 630 nm long pass filter (red). Forward and 90° light scatter were additionally collected. The instrument was set up initially with micro beads (Poly Science Inc., Warrington, PA, USA) followed by cells from identically prepared normal colonic mucosa and we have a large stock of this from a single patient to control all experiments. This has a G1 diploid DNA peak which was routinely recorded in channel 200 on the DNA (red) axis and at about channel 50 on the p62-antiv (green) axis. The signal in the green channel was due to red fluorescence breaking through the filters at the high voltages used on the green photomultiplier. This was an advantage as the instrument could be set up identically for each run by using the diploid DNA peak as a standard for both channels. The data were collected list-mode on a fast R107 disc via a dedicated LSI 11/23 and a time sharing PDP 11/40 computer (all Digital Equipment Corporation, DEC, USA) after digitization of each signal into peak height, area and width (time of flight through the beam) within the analogue-to-digital conversion (ADC) range of 1-1024. During this series of experiments we found that the 1024 linear ADC steps were not sufficient to encompass the range within the biology. Hence, we initiated electronic modifications to incorporate variable sensitivity in the pre-amplifier circuits which increased the range to 8192. However, this was only available for about one third of the specimens hence, the results are presented using the 1024 range. Analysis was carried out with a VAX 8600 (DEC) computer and the software package includes algorithms designed to exclude clumps and debris based on pulse shape analysis from the master triggering detector, red fluorescence, together with light scatter signals. Full details of this 6-dimensional procedure have been published (Watson et al., 1985). In order to facilitate processing in the multi-dimensional mode the data resolution was reduced from 10-bit (1024) to 6-bit (64) precision (Watson et al., submitted). The median of the distribution of specific p62-antiv fluorescence associated with the diploid, triploid and tetraploid regions of the DNA histograms were calculated by subtracting the comparable non-specific signal recorded from the fluorescence controls, those samples stained with fluorescinated 2nd-antibody only.

Results

Specificity controls

Antibody specificity controls have previously been described (Rabbitts et al., 1985; Watson et al., 1985; 1986). Briefly, 4 monoclonal antibodies which do not recognise p62-antiv or nuclear proteins gave no signal above background and specific fluorescence was blocked by preincubation of MYC 1-6E10 with the peptide used as the immunogen. Binding of the antibody was not blocked with an irrelevant peptide corresponding to a different region (carboxy terminus) of the c-myc protein. A second anti-p62-antiv antibody (MYC-CT14) raised to the carboxy terminus amino acid sequences has also been used in a number of related studies as well as with some tumours reported in this paper. The mean ratio for the MYC 1-6E10 versus the MYC-CT14 signals was 4.1±0.36 (95% confidence limits) for 163 samples covering 5 different tumour types.

Patient data

The 12 data panels in Figure 1 each show contour plots of signals from the green detector on the ordinate and red plotted against DNA (red detector) on the ordinate from carcinoma biopsies. The monodimensional histograms are shown adjacent to the respective axes. The 4 columns each represent data from a single patient where panels A, B and C respectively show the PBS control (PI staining only), the fluorescence control (florescinated 2nd antibody plus PI) and the p62-antiv signal (MYC 1-6E10 plus 2nd antibody and PI). The contour display is angled away from the Y-axis in each of the A panels due to breakthrough of the red PI/DNA signal into the green channel. The B panels show a small increase in the signal on the abcissa due to non-specific trapping of the 2nd antibody; the X-axis distributions are slightly right-shifted compared with the respective PI controls. These data were selected and ranked in ascending p62-antiv levels from C1 to C4 to illustrate the maximum range of p62-antiv levels found in the carcinomas, C1 being the lowest and C4 the highest. Figure 2 shows directly comparable data from 4 normal biopsies which have again been ordered from the lowest to the highest p62-antiv values, panels C1 to C4 respectively. The majority of cells exhibited 'off-scale' p62-antiv levels in each panel (see X-axis histograms) in spite of reducing the electronic sensitivity of the instrument to 25% in C3 and to 12.5% in C4.

DNA analyses

The coefficients of variation of the DNA histograms were relatively high in this series of experiments. These varied from 6% to 14% and all data sets were included in the analysis irrespective of the high CVs. In only one sample was there a well defined aneuploid component which was distinct from the diploid peak (see Figure 1, patient 4). However, there was a positive skew of the peak in 19 of the carcinoma specimens which could have been due to aneuploidy, some cells in early S-phase or to increased DNA 'stainability' in a proportion of the population. The position of the mode of these distributions (maximum frequency) varied between 192 and 224, representing a DNA index range of 0.96 to 1.12. However, the medians of these same distributions were in the range 203 to 267 giving a DNA index range of 1.01 to 1.32 with an average of 1.24. The multi-dimensional data processing procedures used in these analyses enforced a reduction in the data precision from 10-bits to 6-bits. Hence, the mode of any distribution could only be recorded in increments of 16 for the ADC range of 2¹⁶. This results in a possible error of ±4% and a maximum error of 7.8% if the true position of the diploid mode is located in channel 192. The mean and median of the same distribution, however, can be calculated within the range of 2¹⁶ with an error of only about ±0.4% (Watson et al., submitted). However, neither the mean nor the median is an accepted parameter for calculating the DNA index. Due to this limitation enforced by our current data processing procedures it would be necessary to achieve CVs of ≤5% when using the modal value to distinguish reliably between diploid and aneuploid populations where the latter had DNA indices up to 1.32
as suggested by the median values in this series of determinations.

**Oncoprotein analysis**

Because of the potential interpretive difficulties inherent in the DNA histograms as outlined above, the medians of the p62\(^{c-myc}\) fluorescence distributions (in arbitrary units) associated with only the mean of the first peak ±2s.d. was calculated at each antibody concentration. These results are shown in Figure 3 where histograms of frequency versus p62\(^{c-myc}\) levels are shown for normal mucosa, CIN I, II and III, and for carcinomas, panels A, B, C, D and E respectively. The values given were those obtained at the antibody concentration which gave the maximum signal. The majority of the normal specimens were scored with values greater than 900 and most of these were off-scale with values in excess of 1024. The carcinomas exhibited a bimodal distribution with the majority scoring below 600. Comparisons of means for such distributions are not particularly meaningful especially as the majority of normal specimens gave off-scale readings. In consequence, \(\chi^2\) was used as a statistical assessment by comparing the frequencies above and below 600 in each histogram. This gave \(\sum \chi^2 = 35\) with 4 degrees of freedom, \(P < 0.00001\) that the observed distributions within the histograms could have arisen by chance. Progression from CIN I to III was accompanied by a shift in p62\(^{c-myc}\) fluorescence to lower values, \(\chi^2 = 4.55\) with 1 degree of freedom, \(P < 0.05\). However, comparison of CIN I with II and of CIN II with III did not reach significance at \(P < 0.05\).

One patient had two biopsies from different regions of the cervix. One was normal with an off-scale p62\(^{c-myc}\) level of 1024. The second biopsy showed CIN III disease with a p62\(^{c-myc}\) level of 268.

The relationships between p62\(^{c-myc}\) levels versus antibody dilutions are given in Figure 4 for normal biopsies, CIN (all grades) and for carcinomas. Histograms are shown of frequency versus maximum p62\(^{c-myc}\) fluorescence signal at whichever antibody dilution the maximum occurred. This shows that the antibody dilutions at which the maximum signal was seen were different in normal and malignant cells. Normal biopsies exhibited higher levels which were attained at higher antibody dilutions. These results are analysed in Table I which is a 3\(\times\)4 frequency matrix of normal, CIN and carcinoma versus grouped low (1:10 + 1:31.6) and high (1:100 + 1:316) antibody dilutions for p62\(^{c-myc}\) levels below 600 and greater than or equal to 600. The expected frequencies are shown in brackets adjacent to those observed and \(\chi^2\) for expected versus observed frequencies in each
Figure 2  Biopsies from normal mucosa from 4 patients where the display is directly comparable with Figure 1. Note that most cells scored 'off-scale' for p62<sup>myc</sup>, see panels C1 through C4, in spite of a reduction in instrument sensitivity to 25% in C3 and to 12.5% in C4.

| Table 1  | Frequency analysis of histograms shown in Figure 4. |
|----------|---------------------------------------------------|
|          | McAb conc. | p62<sup>myc</sup> | Normal | CIN | Tumour | Row totals |
| 1:10     | <600 | 1 (10.16) | 9 (11.17) | 33 (21.67) | 43 |
|          | $\chi^2$ | 8.26 | 0.42 | 5.92 |
| + 1:31.6 | >600 | 5 (5.19) | 0.007 | 0.014 | 0.0007 | 22 |
|          | $\chi^2$ | 0.00 | 0.00 | 0.00 |
| 1:100    | <600 | 1 (4.02) | 5 (4.42) | 11 (8.57) | 17 |
|          | $\chi^2$ | 2.27 | 0.076 | 0.678 |
| + 1:316  | >600 | 22 (10.63) | 14 (11.69) | 9 (22.67) | 45 |
|          | $\chi^2$ | 12.16 | 0.456 | 8.25 |
| Column totals | 29 | 34 | 64 | 127 |

This is a 3 x 4 matrix of normal, CIN and carcinoma versus grouped low (1:10 + 1:31.6) and high (1:100 + 1:316) antibody dilutions for frequencies above and below a p62<sup>myc</sup> level of 600 in each histogram. The expected frequencies are in brackets and $\chi^2$ for observed versus expected frequencies is shown in each element of the matrix. The total $\sum \chi^2$ was 38 with 6 degrees of freedom, $P<0.00001$ that these observed distributions could have arisen by chance.
2/3 of the mucosa the cytoplasmic staining predominated with increasing distance from the basement membrane, but nuclear staining continued to be observed. Stromal cells showed very weak staining. The carcinomas exhibited generally weak staining with large areas in all sections showing very little or no staining. However, focal areas were present in all sections in which both nuclear and cytoplasmic staining was observed. In some of these areas in well differentiated tumours the staining was almost as intense as in normal mucosa. There was no discernible pattern to the patchy focal staining in the carcinomas with no apparent relationship to necrotic areas or vacuarity.

Discussion

The significant finding in this investigation was a progressive decrease in the median of the p62c-myc fluorescence distributions, assayed by the MYC 1-6E10 antibody in archival cervical nuclei, with progression from normal to neoplastic biopsies. Furthermore, these differences are probably underestimated as all normal specimens contained some stromal cells which showed very weak staining. This finding was not expected, particularly as Riou et al. (1984) have reported c-myc gene amplification in over 50% of stage 3 and 4 patients with cervical carcinoma in a small study. Our initial expectation was based on the preconception that disordered proliferation control might be related to an increased expression of the protein in neoplastic cells. However, the function of p62c-myc is not yet understood and we cannot ascribe any functional significance to either our findings or our preconceptions at present. Nevertheless, a number of possibilities exist for the divergent expectation including post-translational protein modification or c-myc gene mutation in malignant cells, increased turnover of the protein which is known to have a short half-life in stimulated cells (Hann et al., 1985; Rabbits et al., 1985) and a possible increase in the susceptibility of the protein to proteolysis in neoplastic cells in the preparation for the assay. Further factors to be considered include greater accessibility of p62c-myc in normal cells and the possibility that the MYC 1-6E10 antibody recognises an epitope of some other nuclear associated protein(s). The specificity controls, including the blocking assays, do not positively exclude the last possibility. However, in 163 tumours from 5 different malignancies, including some tumours from this study, there was a 4.1:1 direct relationship between results with MYC 1-6E10 and an antibody (MYC-CT14) which recognises a different region of the protein, the carboxy terminus. It is unlikely that both antibodies would recognise epitopes on different proteins on a quantitative basis. Furthermore, in studies with fresh colonic mucosa and carcinomas there was good correlation between p62c-myc mRNA and Western blotting (Sikora et al., 1987) with results from flow cytometry (Watson et al., submitted) using the same technique as reported in this paper.

Somewhat similar results to those given here were obtained in teratoma biopsies where underdifferentiated lesions had lower p62c-myc levels compared with well differentiated tumours showing yolk sac elements (Watson et al., 1986). Moreover, in the present study we have shown that the antibody concentrations at which the maximum fluorescence response occurred were different in normal and malignant cells and it may be significant that the MYC 1-6E10 antibody was raised to peptide sequences corresponding to the normal gene. The data in Figure 4 suggest that there may be different protein binding constants for this antibody in normal and malignant cells and an altered protein structure could be implicated. However, these fundamental questions which relate to function are not likely to be resolved with nuclei extracted from wax embedded biopsies.

**Figure 3** Medians of p62c-myc fluorescence distributions associated with the diploid peaks displayed as frequency histograms for normal, CIN I, II and III and for carcinomas, panels a, b, c, d and e respectively.

Subcellular localization

Normal cervical mucosa exhibited consistent patterns of subcellular p62c-myc localization with intense staining which was not dependent on age. No menstrual cycle data were available. Cells in the lower 1/3 of the mucosal layer closest to the basement membrane showed mixed cytoplasmic and nuclear staining but the latter predominated. In the upper
Many oncogene encoded proteins are associated with the transduction and transmission of mitotic stimuli and the scenario of a well ordered and integrated molecular chain controlling proliferation is beginning to emerge. Thus far, c-sis (Doolittle et al., 1983; Waterfield et al., 1983) encodes an extracellular transmitter (PDGF), v-erb B (Downward et al., 1984) and c-fms (Scherr et al., 1985) respectively encode the intracellular domain of epidermal growth factor receptor and the transmembrane receptor for macrophage colony stimulating factor (CSF-1). Recently it has been suggested that p21v-H-ras links the effects of growth factor stimulation with increased phosphoinositol turnover and hence may act as an intracellular transmitter (Wakelam et al., 1986). The final links in this molecular chain reside in the nucleus and oestrogen receptor, now known to be a nuclear protein with some biochemical properties not dissimilar to those of p62c-myc, is encoded by v-erb A (Green et al., 1986). p62c-myc is also known to be nuclear associated, and it elutes from the nucleus at salt concentrations as low as 200 mm (Evan & Hancock, 1985). This is within the intracellular physiological range and suggests a possible role as a DNA binding protein functioning in proliferation control in response to ionic changes associated with mitotic stimulation.

In spite of its nuclear location in tissue culture cells (Evan & Hancock, 1985) there are circumstances where p62c-myc has been observed in the cytoplasm. Using immunoperoxidase staining in formalin fixed archival normal colonic mucosa the protein was present in both the nucleus and cytoplasm with the most intense staining observed in the middle 1/3 of the crypts of Lieberkuhn (Stewart et al., 1986). In testicular cancer studies we found intense nuclear and cytoplasmic staining in well differentiated yolk sac elements (Sikora et al., 1985). In further studies in colonic mucosa we have observed similar patterns in freshly fixed tissue with p62c-myc showing weak but exclusively nuclear staining in the crypt bases. In the middle 1/3 it was located, and intensely stained, in both nucleus and cytoplasm. However, at the crypt surface the protein had become completely redistributed with cytoplasmic staining predominating (Forcacs et al., 1986).

Previously, we thought that the cytoplasmic staining could have been an artefact due to the fixation and preparative processes (Stewart et al., 1986) but this now seems increasingly unlikely as the same phenomenon has been observed repeatedly in colonic tissue freshly fixed with 50% methanol under isotonic conditions. Similar patterns were seen in the immunoperoxidase stained normal cervical sections in this study where cytoplasmic staining predominated with increasing maturation towards the surface of the mucosa. Relocation of the protein in the cytoplasm with exclusion from the nucleus could, therefore, be involved in the maturation and differentiation process.

The quality of some of the DNA histograms was not good in this series of experiments. This was not due to the relatively thin sections (25 µm) used in the determinations as the pulse shape algorithms in the software package exclude nuclear fragments, debris and clumps. These routines predict a decreasing proportion of intact nuclei conforming to a given pulse shape pattern with decreasing section thickness (Watson, et al., 1985). All carcinoma sections examined histologically (53/64) contained some cells with normal morphology hence, we expected to see two peaks in any aneuploid tumours. This was seen in only one tumour (Figure 1, C4), but there was a positive skew to the DNA peak in 30% of specimens which was probably due to aneuploid components. Nevertheless, in spite of our failure to clearly resolve these presumed aneuploid components there was a very clear statistical difference between the normal biopsy and the invasive carcinoma groups based on p62c-myc levels. All the data shown in Figure 3 and 4 were associated with the first peak of the DNA histograms. However, one of the patients included in the normal category had chronic interstitial cervicitis and the p62c-myc level in this specimen was low at 147. All the carcinoma specimens recorded with median p62c-myc values greater than 600 contained a substantial number of cells with very low fluorescence levels, less than 300. In contrast, apart from the
References

AL. I. & PLOEM, J.S. (1979). Detection of suspicious cells and rejection of artefacts in cervical cytology using the Leyden Television Analysis system. J. Histochem. Cytochem., 27, 629.

BARRETT, D.L., JENSEN, R.H., KING, E.B., DEAN, P.N. & MAYALL, B.H. (1979). Flow cytometry of human gynaecologic specimens using log chromogenic A3 fluorescence and log 90 degrees light scatter. J. Histochem. Cytochem., 27, 573.

DOOLITTLE, R.F., HUNKERPILLER, M.W., HOOD, L.E. & 4 others. (1983). Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet derived growth factor. Science, 211, 275.

DOWNWARD, J., YARDEM, Y., MAYS, E. & 6 others. (1984). Close similarities of epidermal growth factor receptor and v-erb B oncogene protein sequences. Nature, 307, 521.

EVAN, G. & HANCOCK, D. (1985). Nuclear structures containing p62oncoprotein. Cell, 43, 253.

EVAN, G., LEWIS, G.K., RAMSAY, G. & BISHOP, J.M. (1985). Isolation of monoclonal antibodies specific for human and mouse proto-oncogenes. Mol. Cell Biol., 5, 3610.

ELIAS-JONES, J., HENDY-IBBS, P., COX, H., EVAN, G.I. & WATSON, J.V. (1986). Cervical brush biopsy specimens suitable for DNA and platelet oncogene analysis using flow cytometry. J. Clin. Pathol., 39, 577.

FORGACS, I.C., SUNDARESAN, V., WIGHT, D.G.D. & 4 others. (1987). Abnormal c-myc oncogene expression in dysplasia and carcinoma associated with ulcerative colitis. Gut (In press).

FUJI, T., CRUM, C.P., WINKLER, B., FU, Y.S. & RICHART, R.M. (1984). Human papillomavirus infection and cervical intraepithelial neoplasia: histopathology and DNA content. Obstet. Gynecol., 63, 99.

GREEN, S., WALTER, P., KURMAN, V. & 4 others. (1986). Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature, 320, 134.

GREENBERG, M.E. & ZIFF, E.B. (1984). Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature, 314, 423.

HANN, S.R., THOMPSON, C.B. & EISENMAN, R.N. (1985). c-myc oncogene protein is independent of the cell cycle in human and avian cells. Nature, 314, 366.

HEADLEY, D.W., FRIEDLANDER, M.I., TAYLOR, I.W., RUGG, C.A. & MUSGROVE, E.A. (1983). Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J. Histochem. Cytochem., 31, 1333.

KELLY, K., COCHRAN, B.H., STILES, C.D. & LEDER, P. (1983). Cell specific regulation of the c-myc gene by lymphocyte mitogens and phorbol ester. Cell, 35, 603.

KELLY, K., COCHRAN, B.H., STILES, C.D. & LEDER, P. (1984). The regulation of c-myc by growth signals. Curr. Topics Microbiol. Immunol., 113, 117.

LINDEN, W.A., OCHLIK, K., BASCH, H. & 7 others. (1979). Flow cytometric prescreening of cervical smears. J. Histochem. Cytochem., 27, 529.

MAKINO, R., HAYASHI, K.A. & SUGIMURA, T. (1984). c-myc is induced in rat liver at a very early stage of regeneration or by cycloheximide treatment. Nature, 310, 697.

NIMAN, H.L., HOUGHTEN, R.A., WALKER, L.E. & 4 others. (1983). Generation of protein-reactive antibodies by short peptides in an event of high frequency: Implications for the structural basis of immune recognition. Proc. Natl. Acad. Sci., 80, 4949.

RABBITS, P.H., WATSON, I.V., LAMOND, A. & 7 others. (1985). Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. Endo, J., 4, 2009.

RIEU, G., BARBOIS, M., TORDJMAN, I., DUTRONQUAY, V. & ORTH, G. (1984). Presence de genomes de papillomavirus et amplification des oncogenes c-myc et c-Ha-ras dans des cancers enervants du col de l’utérus. C. R. Acad. Sc. Paris, 299, 575.

SCHERR, C.J., RETTENMIEER, C.W., SACCA, R., ROUSSEL, M.F., LOOK, A.T. & STANLEY, E.R. (1985). The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor. CSF 1. Cell, 41, 665.

SIKORA, K., CHAN, S., EVAN, G. & 4 others. (1987). c-myc oncogene expression in colorectal cancer. Cancer. (In press).

SIKORA, K., EVAN, G., STEWART, J. & WATSON, I.V. (1985). Detection of c-myc oncoprotein in testicular cancer. Br. J. Cancer, 52, 171.

SMEULDERS, A.W., LEYTE-VELDSTRA, L., PLOEM, J.S. & CORNELISSE, C.J. (1979). Texture analysis of cervical cell nuclei by segmentation of chromatin patterns. J. Histochem. Cytochem., 27, 199.

SPENDER, E. & WITTE, S. (1979). The diagnostic significance of nuclear deoxyribonucleic acid measurement in automated cytology. J. Histochem. Cytochem., 27, 520.

STEWART, J., EVAN, G.I., WATSON, J.V. & SIKORA, K.E. (1986). Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br. J. Cancer, 53, 1.

TSOU, K.C., HONG, D.H., VARELLO, M., GIUNTOLL, R., WHEELER, J.E., ATKINSON, B.F., MANGAN, C. & MIKUTA, J. (1984). Flow cytometric DNA analysis as a diagnostic aid for cervical condyloma and cancer. Cancer, 54, 1778.

TUCKER, I. (1977). An image analysis system for cervical cytology automation using nuclear DNA content. J. Histochem. Cytochem., 27, 613.

WAKEHAM, M.J.O., DAVIES, S.A., HOUSLAY, M.D., MACKAY, L., MARSHALL, C.J. & HALL, A. (1986). Normal p21 approx couples bombesin and other growth factor receptors to inositol phosphate production. Nature, 323, 173.
WATERFIELD, M.D., SCRACE, G.T., WHITTLE, N., STROOBANT, P., JOHNSON, A., WASTESON, A., WESTERMARK, B., HUANG, J. & DEUEL, T.F. (1983). Platelet derived growth factor is structurally related to the putative transforming protein p28S of simian sarcoma virus. *Nature*, 304, 35.

WATSON, J.V. (1980). Enzyme kinetic studies in cell populations using fluorogenic substrates and flow cytometric techniques. *Cytometry*, 1, 143.

WATSON, J.V. (1981). Dual laser beam focusing for flow cytometry through a single crossed cylindrical lens pair. *Cytometry*, 2, 14.

WATSON, J.V. (1985). A method for improving light collection by 600% from square cross section flow cytometry chambers. *Br. J. Cancer*, 51, 433.

WATSON, J.V., STEWART, J., EVAN, G., RITSON, A. & SIKORA, K. (1986). The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. *Br. J. Cancer*, 53, 331.

WATSON, J.V., SIKORA, K.E. & EVAN, G.I. (1985). A simultaneous flow cytometric assay for c-myc oncoprotein and cellular DNA in nuclei from paraffin embedded material. *J. Immunol. Meths.*, 83, 179.

WHEELESS, L.L., PATTEN, S.F., BERKAN, T.K. & 5 others. (1984). Multidimensional slit-scan prescreening system: preliminary results of a single blind clinical study. *Cytometry*, 5, 1.